AI-Powered ECG Model Shows Promise in Heart Failure Risk Prediction: JAMA

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-04-29 02:30 GMT   |   Update On 2025-04-29 02:30 GMT
Advertisement

A new study published in the Journal of American Medical Association showed that a noise-adapted AI-ECG model successfully estimated heart failure risk using only lead I ECGs across diverse multinational cohorts. This suggests a potential strategy for heart failure (HF) risk stratification that could be applied using wearable and portable ECG devices, warranting further prospective studies.

Single-lead electrocardiograms (ECGs) may be recorded using portable equipment, which might allow for extensive community-based risk assessment. Thus, to determine if an artificial intelligence (AI) system can predict heart failure risk from noisy single-lead electrocardiograms, Lovedeep Dhingra and colleagues carried out this investigation.

A retrospective cohort analysis assessed persons without heart failure at baseline from UK Biobank, YNHHS, and ELSA-Brasil, utilizing outpatient ECG data. The data were evaluated between September 2023 and February 2025, with the major exposure being the AI-ECG-predicted risk of left ventricular systolic dysfunction (LVSD).

Lead I ECGs were separated to mimic wearable device signals, and a noise-adaptive AI-ECG model trained to identify LVSD was used. The model's relationship with new-onset heart failure (first HF hospitalization) was investigated. Its predictive ability was compared to the PREVENT and PCP-HF risk scores using the integrated discrimination improvement, Harrell C statistic, and net reclassification improvement.

Baseline ECGs were obtained from 192 667 YNHHS patients, 42 141 UKB participants, and 13 454 ELSA-Brasil participants. 31 (0.2%) in ELSA-Brasil, 46 (0.1%) in UKB, and 3697 (1.9%) in YNHHS experienced heart failure over a median (IQR) of 4.2 (3.7-4.5) years, 3.1 (2.1-4.5) years, and 4.6 (2.8-6.6) years, respectively.

Regardless of age, sex, comorbidities, or competing risk of mortality, a positive AI-ECG screening result for LVSD was linked to a 3- to 7-fold increased risk for HF, and every 0.1 increase in the model likelihood was linked to a 27% to 65% greater hazard across cohorts. The discrimination of AI-ECG for new-onset HF was 0.828 in ELSA-Brasil, 0.723 in YNHHS, and 0.736 in UKB.

Across cohorts, integrating AI-ECG predictions beside PCP-HF and PREVENT equations resulted in a higher Harrel C statistic. AI-ECG improved integrated discrimination by 0.091 to 0.205 vs PCP-HF and 0.068 to 0.192 vs PREVENT, as well as net reclassification by 18.2% to 47.2% vs PCP-HF and 11.8% to 47.5% vs PREVENT.

Overall, a noise-adapted AI-ECG model predicted HF risk using lead I ECGs across global cohorts, indicating a viable HF risk-stratification technique that needs to be studied prospectively employing wearable and portable ECG devices.

Source:

Dhingra, L. S., Aminorroaya, A., Pedroso, A. F., Khunte, A., Sangha, V., McIntyre, D., Chow, C. K., Asselbergs, F. W., Brant, L. C. C., Barreto, S. M., Ribeiro, A. L. P., Krumholz, H. M., Oikonomou, E. K., & Khera, R. (2025). Artificial intelligence-enabled prediction of heart failure risk from single-lead electrocardiograms. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2025.0492

Tags:    
Article Source : JAMA Cardiology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News